in which Sanofi and Novo Nordisk have eclipsed Lilly, a pioneer in the field. The list price of Basaglar will be $316.85 for a pack of five pens, 15% below the list price of Lantus. The companies ...

More than three years after approving two biosimilars referencing Sanofi ... Eli Lilly revealed a plan to cut the cost of most of its insulins by 70%. Less than two weeks later, Novo Nordisk ...

The Tempo system brings together a pre-filled insulin pen, the TempoSmart ... management ecosystems." Lilly is trying to stay ahead of rivals Novo Nordisk and Sanofi in an increasingly competitive ...

The AG's office filed a lawsuit in 2018 against insulin manufacturers Eli Lilly, Sanofi and Novo Nordisk, alleging the companies deceptively raised the price of insulin. In 2024, the AG's office ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

South Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday ...

Shares in the three companies fell, Lilly down 1 percent at $74.60, while U.S. listed shares of Novo Nordisk were off 0.4 percent at $35.62 and Sanofi recovered a bit to trade up 0.4 percent at ...